SCHOTT Pharma Forecast, price target & analysts
SCHOTT Pharma Target price 2025 - Analyst rating & recommendation
SCHOTT Pharma Classifications & Recommendation:
SCHOTT Pharma Price Target
| Target Price | €26.48 |
| Price | €24.44 |
| Potential |
8.37%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target SCHOTT Pharma 2026 .
The average SCHOTT Pharma target price is €26.48.
This is
8.37%
register free of charge
€37.00
51.39%
register free of charge
€20.00
18.17%
register free of charge
|
|
| A rating was issued by 11 analysts: 4 Analysts recommend SCHOTT Pharma to buy, 4 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the SCHOTT Pharma stock has an average upside potential 2026 of
8.37%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Sep '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million € | 957.09 | 1,019.93 |
| 6.46% | 6.57% | |
| EBITDA Margin | 24.66% | 26.68% |
| 4.95% | 8.21% | |
| Net Margin | 15.58% | 14.73% |
| 7.93% | 5.45% |
10 Analysts have issued a sales forecast SCHOTT Pharma 2025 . The average SCHOTT Pharma sales estimate is
This results in the following potential growth metrics:
10 Analysts have issued an SCHOTT Pharma EBITDA forecast 2025. The average SCHOTT Pharma EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 SCHOTT Pharma Analysts have issued a net profit forecast 2025. The average SCHOTT Pharma net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Sep '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share € | 0.99 | 1.00 |
| 1.98% | 1.01% | |
| P/E | 25.06 | |
| EV/Sales | 3.68 |
7 Analysts have issued a SCHOTT Pharma forecast for earnings per share. The average SCHOTT Pharma <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the SCHOTT Pharma stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Current SCHOTT Pharma Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| EQUI.TS | Locked ➜ Locked | Locked | Dec 19 2024 |
| DZ BANK | Locked ➜ Locked | Locked | Dec 18 2024 |
| BERENBERG | Locked ➜ Locked | Locked | Dec 15 2024 |
| ODDO BHF | Locked ➜ Locked | Locked | Dec 11 2024 |
| STIFEL EUROPE | Locked ➜ Locked | Locked | Dec 11 2024 |
| BNP PARIBAS EXANE | Locked ➜ Locked | Locked | Dec 08 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
EQUI.TS: Locked ➜ Locked
|
Dec 19 2024 |
|
Locked
DZ BANK: Locked ➜ Locked
|
Dec 18 2024 |
|
Locked
BERENBERG: Locked ➜ Locked
|
Dec 15 2024 |
|
Locked
ODDO BHF: Locked ➜ Locked
|
Dec 11 2024 |
|
Locked
STIFEL EUROPE: Locked ➜ Locked
|
Dec 11 2024 |
|
Locked
BNP PARIBAS EXANE: Locked ➜ Locked
|
Dec 08 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
